MedTrace Logo

Steatohepatitis in Chronic Hepatitis B

NCT05317260 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 408

Last updated 2022-04-07

No results posted yet for this study

Summary

Fatty liver disease is increasingly recognized in patients with chronic hepatitis B (CHB). Whether concurrent fatty liver disease affects the long-term outcomes of CHB is unclear. The investigators performed a longitudinal study to investigate the prognostic relevance of concurrent fatty liver disease for patients with CHB receiving antiviral therapy.

Conditions

Interventions

DRUG

Antiviral Agents

The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Phunchai Charatcharoenwitthaya, MD. · Siriraj Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-01
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • Thailand

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05317260 on ClinicalTrials.gov